Main Menu

Kinnate Biopharma Inc.


Rigrodsky Law, P.A. is investigating Kinnate Biopharma Inc. (“Kinnate”) regarding possible breaches of fiduciary duties and other violations of law related to Kinnate’s agreement to be acquired by XOMA Corporation. Under the terms of the agreement, Kinnate shareholders will receive (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a non-transferable contingent value right, representing the right to receive 85% of the net proceeds from any out license or sale of the Kinnate programs effected within one year of closing of the merger or 100% of the net proceeds from any out license or sale executed prior to the closing.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 04/25/2024

* Indicates a required field.

Back to Page